This quality standard covers managing prostate cancer in people referred to secondary care or having follow-up for prostate cancer in primary care. It describes high-quality care in priority areas for improvement.

 We’ve produced new guidance on delivery of radiotherapy to follow during the COVID-19 pandemic. This is relevant to statement 3 in this quality standard and may help to support using the quality standard during this time.

It does not cover recognising and referring for suspected cancer in primary care, which is covered by NICE’s quality standard on suspected cancer.

In May 2019 this quality standard was updated to reflect changes to the updated NICE guideline on prostate cancer. Statement 2 was amended so that active surveillance is an equal choice alongside prostatectomy and radiotherapy for people with low-risk localised prostate cancer. Terminology, references and links to source guidance have also been updated throughout.

How to use NICE quality standards and how we develop them

Quality standards help you improve the quality of care you provide or commission. Find out how to use quality standards and how we develop them. We check our quality standards every August to make sure they are up to date.